摘要
特发性肺纤维化(Idiopathic pulmonary fibrosis, IPF)是一种病因不明的间质性肺炎,其中位生存期2~4年。早期IPF一般是无症状的,常常导致诊断及治疗延迟。到目前为止,还没有很好的临床生物标记物可以准确地对IPF进行诊断、评估病情及预后。但是随着IPF研究的不断深入及大量样本的佐证,它们有可能成为有助于诊断、监测疾病进展和治疗效果的有用工具。本文对IPF相关的新的临床生物标志物进行综述,为提高临床诊治提供一定参考。
Idiopathic pulmonary fibrosis (IPF) is an interstitial pneumonia of unknown etiology, with a median survival of 2~4 years. Early IPF is usually asymptomatic and often results in delayed diagnosis and treatment. So far, there is no good clinical biomarker that can accurately diagnose, evaluate the condition and prognosis of IPF. However, with further research on IPF and the support of large numbers of samples, they may become useful tools for diagnosis, monitoring of disease progression and treatment effectiveness. In this paper, new clinical biomarkers related to IPF were reviewed to provide some reference for improving clinical diagnosis and treatment.
出处
《临床医学进展》
2022年第1期19-24,共6页
Advances in Clinical Medicine
